Tazarotene
Title: Tazarotene
CAS Registry Number: 118292-40-3
CAS Name: 6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester
Additional Names: ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate
Manufacturers' Codes: AGN-190168
Trademarks: Avage (Allergan); Tazorac (Allergan); Zorac (Allergan)
Molecular Formula: C21H21NO2S
Molecular Weight: 351.46
Percent Composition: C 71.76%, H 6.02%, N 3.99%, O 9.10%, S 9.12%
Literature References: Acetylenic retinoid prodrug converted to the active metabolite, tazarotenic acid, with selective affinity for retinoic acid receptors RARb and RARg. Prepn: R. A. S. Chandraratna, EP 284288; idem, US 5089509 (1988, 1992 both to Allergan). Clinical evaluation in psoriasis: T. Esgleyes-Ribot et al., J. Am. Acad. Dermatol. 30, 581 (1994). Clinical trial in treatment of photodamage: S. Kang et al., ibid. 52, 268 (2005). Review of pharmacokinetics and metabolism: D. D.-S. Tang-Liu et al., Clin. Pharmacokinet. 37, 273-287 (1999); of mechanism of action and treatment strategies: A. Roeder et al., Skin Pharmacol. Physiol. 17, 111-118 (2004).
Properties: White solid.
Therap-Cat: Antiacne; antipsoriatic. In treatment of photodamaged skin.
Keywords: Antiacne; Antipsoriatic.

Others monographs:
Ferrosoferric Oxideγ-HydroxybutyrateZinc AcetateThioglycolic Acid
p-BiphenylamineButalbitalClobenfurolMycolic Acids
AcetimidoquinoneLeuprolideDeferasiroxp-Bromobenzenesulfonyl Chloride
IsoquassinSofalconeLead BoratePentane
©2016 DrugLead US FDA&EMEA